Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

ucted by Shionogi & Co. Ltd. in Japan.
  • Pirfenidone was safe and generally well tolerated in both CAPACITY studies. There was no difference in SAEs and fewer deaths were observed with pirfenidone compared to placebo. Adverse events were comparable to previous clinical studies of pirfenidone.
  • New, pre-specified exploratory efficacy data from CAPACITY pertaining to dose-effect relationships, mean change in FVC volume and Six-Minute Walk Test distance that was presented provided valuable insight into the estimate of treatment effect in the combined populations.
  • ITMN-191:

    • InterMune announced today the successful completion of chronic toxicology studies in two specific species: a six-month chronic toxicology study in rats and a nine-month chronic toxicology study in monkeys. There were no significant drug-related findings in either study. These results provide the necessary preclinical data to conduct the intended Phase 2 and Phase 3 clinical programs for ITMN-191.
    • InterMune expects that the first patient will be enrolled in August in the Phase 2b study of ITMN-191 in combination with standard of care. The Phase 2b trial will study both twice-daily (600mg and 900mg q12h) and three-times-daily regimens (300mg q8h) and both 12-week and 24-week treatment durations.
    • InterMune and its collaboration partner Roche announced today their plan to initiate during the third quarter, a Phase 1b multiple-ascending-dose (MAD) study of once-daily and twice-daily ITMN-191 co-administered with a low dose of ritonavir in combination with standard dose Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) in HCV-infected patients. Ritonavir is an antiviral compound commonly used at low doses to enhance or "boost" the pharmacokinetic (PK) profiles of several marketed HIV protease inhibitors and at least one
      '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. InterMune to Release Second Quarter Financial Results on August 6
    2. InterMune to Present at Goldman Sachs Healthcare Conference
    3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
    4. InterMune to Release First Quarter Financial Results on April 30
    5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
    6. InterMune to Present at Canaccord Adams Hepatitis C Conference
    7. InterMune to Present at Citis 4th Annual Biotech Day
    8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
    9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
    10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
    11. InterMune Announces Issuance of U.S. Patent for ITMN-191
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... -- , Not for release, publication or distribution ... jurisdiction where to do so would constitute a violation of ... ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG ... has held a meeting with representatives of AbbVie. ... agreement or approval of AbbVie. A further update ...
    (Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
    (Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
    (Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
    Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
    ... Mass., April 8, 2008 Caliper Life,Sciences, Inc. (Nasdaq: ... Meeting,of Stockholders will be held on June 3, 2008, ... 68 Elm Street, Hopkinton, Massachusetts. The record,date for Caliper ... 16,2008., About Caliper Life Sciences, Caliper Life ...
    ... national retail drug ... chain, ... of patented pain relief products, today announced that Walgreens,the nation,s largest drugstore ... all of its 6,237 stores.,Its introduction onto Walgreens, shelves across the United ...
    ... brings critical experience in strategic and operational leadership to support ... ... opportunities, COLUMBIA, Md., April 8, 2008 Cylex(TM) ... Company. Cylex is a,global life sciences company that develops and manufactures ...
    Cached Biology Technology:ALCiS(R) Daily Relief Now Available at Walgreens 2Cylex Announces Brad L. Stewart as President of the Company 2
    (Date:7/10/2014)... July 2, 2014  Unisys Corporation,s (NYSE: UIS ... Nederland N.V., today announced that it has been selected by ... manage a new Basic Provision Biometrics solution for penitentiaries across ... won the contract with a solution based on its open ... term of the contract is up to seven years, with ...
    (Date:7/10/2014)... , July 3, 2014 Research ... addition of the "Global Gesture Recognition & ... - Forecasts to 2020" report to their ... Global Gesture Recognition & Touch-Less Sensing Market ... around for a while, but the companies were ...
    (Date:7/10/2014)... 2014  Acuity Market Intelligence today released forecasts from "The ... that the global market for National Electronic ID (eID) programs ... During this time, the number of National eID cards in ... Asia , with its vast population, will dominate ... issued, while Europe trails a distant ...
    Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
    ... the earliest general anaesthetics to be used by the medical ... doctors for more than 150 years how such anaesthetics ... by Leeds University PhD student Dr Yahya Bahnasi, has provided ... and offer the opportunity to design new generations of ...
    ... is a slow and expensive part of drug screening ... to a new combination of experimental and computational protocols ... presented at RECOMB 2008 (Research in Computational Molecular Biology) ... researchers have devised a way to cut the time ...
    ... Egyptian scientists speaking today (Monday 31 March 2008) at ... this week at the Edinburgh International Conference Centre. ... helps the action of important antibiotics in their fight ... more effective. Green tea is a very common ...
    Cached Biology News:Chloroform provides clue to 150 year old medical puzzle 2UC San Diego researchers eliminate drug discovery bottleneck 2UC San Diego researchers eliminate drug discovery bottleneck 3UC San Diego researchers eliminate drug discovery bottleneck 4Green tea helps beat superbugs 2
    Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
    Normal donkey serum collected from healthy normal donkeys....
    This BioSolution package is excellent for doing fluorescence thermal melt experiments on nucleic acids, studies involving biomolecular interactions, protein folding experiments, and more!...
    ... OxyBURST Green reagent (F-2902) was developed in ... to permit measurement of the kinetics of ... oxidative burst directly in the phagovacuole.2 The ... bovine serum albumin (BSA) that has been ...
    Biology Products: